SKIN.SW Cassiopea SIX +9.85% after-hours 13 Feb 2026: volume spike hints buying

The SKIN.SW stock jumped 9.85% in after-hours trading on 13 Feb 2026, closing at CHF 35.70 on heightened activity. Volume reached 2,756 shares, above the three-month average, making SKIN.SW a clear high-volume mover in this session. Traders reacted to higher-than-average turnover rather than an official company release. We assess drivers, valuation, and technicals to explain the move and outline near-term scenarios for Cassiopea S.p.A. on the SIX exchange in Switzerland.

Price action and session context for SKIN.SW stock

SKIN.SW stock climbed from an open of CHF 32.00 to a day high of CHF 36.00, settling at CHF 35.70 after hours. The intraday gain of CHF 3.20 represents a +9.85% move versus the previous close of CHF 32.50. Volume of 2,756 exceeded the average of 1,818, giving a relative volume of 1.52 and confirming the stock’s inclusion among high-volume movers tonight.

Fundamentals and valuation snapshot for SKIN.SW

Cassiopea reports a trailing EPS of -1.27 and a negative PE of -28.13, reflecting clinical-stage losses. The price-to-book ratio sits at 26.04, and book value per share is 1.50. The 50-day average price is CHF 34.37 and the 200-day average is CHF 37.22, placing the current price between short- and long-term averages. These metrics show high valuation sensitivity and biotech-stage risk for investors.

Technicals, liquidity and short-term setup for SKIN.SW stock

The stock tested the intraday high CHF 36.00 and cleared the 50-day average on volume, a short-term bullish sign. Year range runs from CHF 25.70 to CHF 53.00, so upside remains but is capped by earlier highs. Average daily volume is low at 1,818, so spikes produce outsized price moves. Traders should expect continued volatility and watch liquidity before scaling positions.

Sector comparison and market context for SKIN.SW stock

Cassiopea trades in the Healthcare sector where the Swiss index shows modest YTD strength of +2.30%. Healthcare peers carry an average PE of 33.57, well above Cassiopea’s negative PE, reflecting divergent profit profiles. Sector flows can lift clinical-stage names on trial updates or regulatory cues, which can explain episodic volume surges without company announcements.

Risks, catalysts and trading considerations for SKIN.SW

Primary risks include ongoing clinical development costs and negative earnings, shown by negative operating cash flow per share of -0.95. Catalysts to monitor include trial readouts for Winlevi, Breezula or CB-06 programs and licensing news. Given the elevated price-to-book ratio and thin liquidity, position sizing and stop management are essential for short-term traders.

Meyka AI grade and model outlook for SKIN.SW stock

Meyka AI rates SKIN.SW with a score of 62.46 out of 100, Grade B — HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a base-case price target of CHF 42.00, implying an upside of +17.65% versus the current CHF 35.70. This forecast is model-based and not a guarantee.

Final Thoughts

SKIN.SW stock moved sharply after hours on 13 Feb 2026, rising 9.85% to CHF 35.70 on a 2,756-share session. The rise came on volume above the recent average, making SKIN.SW a high-volume mover in the biotech group. Fundamentals remain mixed: trailing EPS is -1.27, PE is negative, and price-to-book is 26.04, which signals valuation risk for longer-term investors. The healthcare sector is modestly positive YTD at +2.30%, which can support episodic rallies in small clinical-stage names. Meyka AI’s model projects a base-case CHF 42.00 price target, an implied +17.65% upside from today’s close. A conservative downside scenario at CHF 30.00 would imply -15.97% downside. Given thin liquidity and ongoing clinical risk, the stock suits active traders and risk-tolerant investors who use strict size limits. For ongoing updates visit the company site at Cassiopea and our SKIN.SW coverage at Meyka AI stock page. Meyka AI is an AI-powered market analysis platform and provides these model-based projections as informational only.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.